---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042631"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:34:39.171074+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galecto's Phase 2b GALACTIC-1 trial misses primary endpoint; GB0139 discontinued

## Summary
- GALACTIC-1 trial did not meet primary endpoint of FVC decline; change from baseline -316.6 mL vs -127.4 mL (placebo).
- Serious adverse events: 7.8% in GB0139 arm vs 1.4% placebo; worsening IPF observed.
- Cash and investments ~$49M as of July 31, 2023; evaluating resource allocation to extend runway into 2025.
- Shifting focus to liver diseases; GULLIVER-3 Phase 2a trial of GB1211 expected to start early 2024.
- No confirmation of target engagement; galectin-3 levels increased in both arms from day 0 to week 52.

## SEC filing metadata
- accession: 0000950170-23-042631
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017023042631/0000950170-23-042631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017023042631/glto-20230815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042631
- JSON: https://secwatch.observer/filing/0000950170-23-042631.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.